Cyclopharm Ltd has released a press release.
Technegas USA Trial Successfully Meets Primary Endpoint
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cyclopharm
- CYC 1H2020 Business Update
- USFDA Approval to File Received for Technegas
- Technegas Approved in Russia
- USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver
- Cyclopharm Lodges NDA for Technegas with the USFDA
Later from Cyclopharm
- Cyclopharm Investor Presentation
- USFDA Approval Progress for Technegas and Business Update
- SNMMI Requests USFDA to Expedite Approval For Technegas
- Cyclopharm Successfully Completes A$30 Million Placement
- Cyclopharm Receives $3.1M R&D Tax Incentive for FY2020
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm